Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | RGS12 | O14924 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9841040 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1AOC3GAAADRA2C | |
| SCHEMBL2636608 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1AOC3GAAADRA2C | |
| SCHEMBL24330472 | 0.86 | KDM4E (0.44) | KDM4EALDH1A1AOC3GAALMNA | |
| SCHEMBL30062527 | 0.84 | ALDH1A1 (0.61) | KDM4EALDH1A1AOC3GAAADRA2C | |
| SCHEMBL3039092 | 0.83 | NPY5R (0.57) | LMNAHIF1ACYP2C19KMT2ANPSR1 | |
| SCHEMBL26988083 | 0.82 | TSHR (0.46) | KDM4EALDH1A1AOC3GAAADRA2C | |
| SCHEMBL26988540 | 0.82 | TSHR (0.46) | KDM4EALDH1A1AOC3GAAADRA2C | |
| SCHEMBL428101 | 0.82 | TSHR (0.46) | KDM4EALDH1A1AOC3GAAADRA2C | |
| SCHEMBL26987985 | 0.82 | TSHR (0.46) | KDM4EALDH1A1AOC3GAAADRA2C | |
| SCHEMBL26989268 | 0.82 | TSHR (0.46) | KDM4EALDH1A1AOC3GAAADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257841-B1 | SYNTHESIS PROCESS FOR CHIRAL CYCLOPROPYL ETHYNYL TERTIARY ALCOHOL COMPOUND | SHANGHAI DESANO PHARMACEUTICAL CO LTD (CN) | 2020-07-08 | — | — | EP | claimed |
| US-20120264933-A1 | EFFICIENT PROCESS TO INDUCE ENANTIOSELECTIVITY IN PROCARBONYL COMPOUNDS | LAURUS LABS PRIVATE LIMITED (IN) | 2012-10-18 | — | — | US | claimed |
| EP-0981520-B1 | EFFICIENT ENANTIOSELECTIVE ADDITION REACTION USING AN ORGANOZINC REAGENT | MERCK & CO INC (US) | 2004-07-07 | — | — | EP | claimed |
| CN-1106389-C | Efficient enantioselective addition reactions using organozinc reagents | MERCK & CO INC (US) | 2003-04-23 | — | — | CN | claimed |
| CN-1255919-A | Efficient enantioselective addition reaction using organozinc reagent | MERCK & CO INC (US) | 2000-06-07 | — | — | CN | claimed |
| US-6015926-A | ADDING DIALKYLZINC TO CHIRAL ADDITIVE, ADDING SECOND ADDITIVE TO FORM CHIRAL ZINC COMPLEX, MIXING WITH ORGANOMETALLIC REAGENT, REACTING WITH CARBONYL COMPOUND TO FORM DESIRED ALCOHOL | MERCK & CO., INC. (US) | 2000-01-18 | — | — | US | claimed |
| EP-3257841-B1 | SYNTHESIS PROCESS FOR CHIRAL CYCLOPROPYL ETHYNYL TERTIARY ALCOHOL COMPOUND | SHANGHAI DESANO PHARMACEUTICAL CO LTD (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-20180029975-A1 | SYNTHESIS PROCESS FOR CHIRAL CYCLOPROPYL ETHYNYL TERTIARY ALCOHOL COMPOUND | SHANGHAI DESANO PHARMACEUTICAL CO., LTD. (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-3257841-A1 | SYNTHESIS PROCESS FOR CHIRAL CYCLOPROPYL ETHYNYL TERTIARY ALCOHOL COMPOUND | Shanghai Desano Pharmaceutical Co., Ltd. (CN) | 2017-12-20 | — | — | EP | disclosed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| CN-105330554-A | Synthesis method of chiral cyclopropylacetylenyl tert-alcohol compound | SHANGHAI DESANO PHARMACEUTICAL INVEST CO LTD | 2016-02-17 | — | — | CN | disclosed |
| US-9073817-B2 | Efficient process to induce enantioselectivity in procarbonyl compounds | LAURUS LABS PRIVATE LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| EP-1017666-B1 | PROCESS FOR ENHANCING THE OPTICAL PURITY OF 2R- 1-HYDROXY- 1-TRIFLUOROMETHYL- 3-CYCLOPROPYLPROPYN-2YL] -4-CHLOROANILINE | MERCK & CO INC (US) | 2003-11-05 | — | — | EP | disclosed |
| CN-1106389-C | Efficient enantioselective addition reactions using organozinc reagents | MERCK & CO INC (US) | 2003-04-23 | — | — | CN | disclosed |
| CN-1276781-A | Process for enhancing optical purity of 2R-[1-hydroxy-1-trifluoromethyl-3-cyclopropylpropyn-2-yl]-4-chloroaniline | MERCK & CO INC (US) | 2000-12-13 | — | — | CN | disclosed |
| CN-1255919-A | Efficient enantioselective addition reaction using organozinc reagent | MERCK & CO INC (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0981520-A1 | EFFICIENT ENANTIOSELECTIVE ADDITION REACTION USING AN ORGANOZINC REAGENT | Merck & Co., Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| US-6015926-A | ADDING DIALKYLZINC TO CHIRAL ADDITIVE, ADDING SECOND ADDITIVE TO FORM CHIRAL ZINC COMPLEX, MIXING WITH ORGANOMETALLIC REAGENT, REACTING WITH CARBONYL COMPOUND TO FORM DESIRED ALCOHOL | MERCK & CO., INC. (US) | 2000-01-18 | — | — | US | disclosed |
| WO-1998051676-A1 | EFFICIENT ENANTIOSELECTIVE ADDITION REACTION USING AN ORGANOZINC REAGENT | MERCK & CO., INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180029975-A1 | SYNTHESIS PROCESS FOR CHIRAL CYCLOPROPYL ETHYNYL TERTIARY ALCOHOL COMPOUND | ADH5, ADH1A, ADH1C | KDM4E 1703/4885ALDH1A1 69/4885AOC3 1004/4885 |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | CYP3A4, CYP2C19, CYP3A43 | KDM4E 1252/4885ALDH1A1 1319/4885AOC3 1313/4885 |
| US-20120264933-A1 | EFFICIENT PROCESS TO INDUCE ENANTIOSELECTIVITY IN PROCARBONYL COMPOUNDS | OTC, MCCC2, SLC6A5 | KDM4E 1301/4885ALDH1A1 690/4885AOC3 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.